Skip to main content

Advertisement

SpringerLink
Log in

Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells

  • Molecular Toxicology
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Non-small cell lung cancer (NSCLC) patients with epithermal growth factor receptor (EGFR) mutations can be treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), however, development of acquired resistance could significantly limit curative effects of EGFR-TKIs. Different mechanisms of acquired resistance to first-generation and second-generation EGFR TKIs have been widely reported, but there were few reports on the resistant mechanism of third-generation EGFR-TKI such as osimertinib (AZD9291). In the present study, significant upregulation of Bcl-2 was found in AZD9291-resistant H1975 cells (H1975AR) compared with H1975, which may constitute an important resistant mechanism of acquired resistance to AZD9291. More importantly, our study showed that synergism between AZD9291 and Bcl-2 inhibitor ABT263 (0.25 μM) or ABT199 (1 μM) could effectively overcome the acquired resistance of AZD9291 in H1975AR in vitro. Flow cytometry analyses demonstrated that AZD9291 + ABT263/ABT199 caused a significantly different cell cycle distribution and produced significantly more apoptosis compared with either AZD9291 or ABT263/ABT199 treatment alone. Further multiscreen/Western blot analyses revealed that NF-κB was significantly downregulated in AZD9291 + ABT263/ABT199 treatment groups compared with AZD9291 or ABT263/ABT199 treatment alone, with a more significant reduction of NF-κB in AZD9291 + ABT199 compared with AZD9291 + ABT263. It is also noticeable that AZD9291 + ABT263 specifically caused a significantly reduced expression of p21 compared with AZD9291 or ABT263 treatment alone while AZD9291 + ABT199 specifically caused significantly reduced expressions of SQSTM1 and survivin, but increased expression of autophagosome marker LC3-II compared with AZD9291 or ABT199 treatment alone. Furthermore, cytotoxicity of AZD9291 + ABT199 could be partially reversed by autophagy inhibitor chloroquine. These results suggest that ABT263 and ABT199 may work through different signaling pathways to achieve synergistic cytotoxicity with AZD9291 in H1975AR. These findings suggest that Bcl-2 inhibitor may provide an effective option in combination therapy with EGFR-TKIs to treat NSCLC with EGFR-TKI acquired resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Bate-Eya LT, den Hartog IJ, van der Ploeg I et al (2016) High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget 7(19):27946

    Article  Google Scholar 

  • Bodzak E, Blough MD, Lee PW, Hill R (2008) p53 Binding to the p21 promoter is dependent on the nature of DNA damage. Cell Cycle 7(16):2535–2543

    Article  Google Scholar 

  • Brown SP, Taygerly JP (2012) Small-molecule antagonists of Bcl-2 family proteins annual reports in medicinal chemistry, vol 47. Elsevier, The amesterdem, pp 253–266

    Google Scholar 

  • Chen J, Jin S, Abraham V et al (2011) The Bcl-2/Bcl-XL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10(12):2340–2349

    Article  CAS  Google Scholar 

  • Cheong HT, Xu F, Choy CT et al (2018) Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI. Oncol Lett 15(1):901–907

    PubMed  Google Scholar 

  • Crombie J, Davids MS (2017) Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol 13(14):1223–1232

    Article  CAS  Google Scholar 

  • Froehlich TC, Müller-Decker K, Braun JD et al (2019) Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma. Blood 134(5):445–455

    Article  CAS  Google Scholar 

  • Galvani E, Sun J, Leon LG et al (2015) NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget 6(40):42717

    Article  Google Scholar 

  • Garg H, Suri P, Gupta JC, Talwar G, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16(1):49

    Article  Google Scholar 

  • Jaiswal PK, Goel A, Mittal R (2015) Survivin: a molecular biomarker in cancer. Indian J Med Res 141(4):389

    Article  Google Scholar 

  • Kögel D, Prehn JH (2013) Caspase-independent cell death mechanisms Madame Curie Bioscience Database [Internet]. Landes Bioscience

  • Li J, Chen Y, Wan J et al (2014) ABT-263 enhances sorafenib-induced apoptosis associated with A kt activity and the expression of B ax and p21 (CIP1/WAF1) in human cancer cells. Br J Pharmacol 171(13):3182–3195

    Article  CAS  Google Scholar 

  • Lin Q-h, Que F-c, Gu C-p et al (2017) ABT-263 induces G 1/G 0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharmacol Sin 38(12):1632–1641

    Article  CAS  Google Scholar 

  • Liu X, Chen X, Shi L et al (2019) The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res 38(1):219

    Article  Google Scholar 

  • Liu Z, Gao W (2017) Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol 335:16–27

    Article  CAS  Google Scholar 

  • Liu Z, Gao W (2019) Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol 93:1555–1571

    Article  CAS  Google Scholar 

  • Lv T, Wang Q, Cromie M et al (2015) Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. Oncotarget 6(32):33006

    Article  Google Scholar 

  • Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677

    Article  CAS  Google Scholar 

  • Patel H, Pawara R, Ansari A, Surana S (2017) Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem 142:32–47

    Article  CAS  Google Scholar 

  • Qi R, Liu XY (2006) New advance in caspase-independent programmed cell death and its potential in cancer therapy. Int J Biomed Sci 2(3):211

    CAS  PubMed  PubMed Central  Google Scholar 

  • Santarpia M, Liguori A, Karachaliou N et al (2017) Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer (Auckl) 8:109

    CAS  Google Scholar 

  • Siddiqui WA, Ahad A, Ahsan H (2015) The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol 89(3):289–317

    Article  CAS  Google Scholar 

  • Su J, Liu F, Xia M et al (2015) p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells. Oncol Rep 34(1):235–243

    Article  CAS  Google Scholar 

  • Suvarna V, Singh V, Murahari M (2019) Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur J Pharmacol 862:172655

    Article  Google Scholar 

  • Tang Z-H, Cao W-X, Su M-X, Chen X, Lu J-J (2017) Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicol Appl Pharmacol 321:18–26

    Article  CAS  Google Scholar 

  • Tsapras P, Nezis IP (2017) Caspase involvement in autophagy. Cell Death Differ 24(8):1369–1379

    Article  CAS  Google Scholar 

  • Wang C, Huang S-B, Yang M-C et al (2015) Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PLoS ONE 10(3):e0120913

    Article  Google Scholar 

  • Wu H, Che X, Zheng Q et al (2014) Caspases: a molecular switch node in the crosstalk between autophagy and apoptosis. Int J Biol Sci 10(9):1072

    Article  Google Scholar 

  • Wu S-G, Shih J-Y (2018) Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38

    Article  Google Scholar 

  • Xu M, Xie Y, Ni S, Liu H (2015) The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med 3(7):96

    PubMed  PubMed Central  Google Scholar 

  • Xu W, Tang W, Li T, Zhang X, Sun Y (2019) Overcoming resistance to AC0010, a third generation of EGFR Inhibitor, by targeting c-MET and BCL-2. Neoplasia 21(1):41–51

    Article  CAS  Google Scholar 

  • Yang L, Ying S, Hu S et al (2019) EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer. Signal Transduct Target Ther 4(1):1–11

    Article  Google Scholar 

  • Yoneda K, Imanishi N, Ichiki Y, Tanaka F (2019) Treatment of non-small cell lung cancer with EGFR-mutations. J UOEH 41(2):153–163

    Article  Google Scholar 

  • Zhan Y, Wang Y, Qi M et al (2019) BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation. Cell Biosci 9(1):60

    Article  Google Scholar 

  • Zhang J, Wang S, Wang L et al (2015) Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. Onco Targets Ther 8:3361

    Article  Google Scholar 

  • Zhang Z, Zhang M, Liu H, Yin W (2019) AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. J Cell Biochem 120(1):756–767

    Article  CAS  Google Scholar 

  • Zhou Q, Wu L, Feng L et al (2019) Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC). J Clin Oncol 43:180–187

    Google Scholar 

  • Zou M, Xia S, Zhuang L et al (2013) Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung casncer cell line harboring T790M mutation. Int J Oncol 42(6):2094–2102

    Article  CAS  Google Scholar 

Download references

Acknowledgement

This research was partially supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R15ES026789. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Occupational and Environmental Health Sciences, School of Public Health, West Virginia University, 3302 Health Sciences Center, HSC South, 64 Medical Center Drive, P. O. Box 9190, Morgantown, WV, 26506, USA

    Zhongwei Liu & Weimin Gao

Authors
  1. Zhongwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weimin Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weimin Gao.

Ethics declarations

Conflict of interest

The authors that there is no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Z., Gao, W. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells. Arch Toxicol 94, 3125–3136 (2020). https://doi.org/10.1007/s00204-020-02816-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-020-02816-0

Keywords

Search

Navigation